Market Research Industry Today
Epigenetic Drugs and Diagnostics Technologies Market to Grow at a CAGR of 19.4% due to Rising Population of Geriatrics - Transparency Market Research
A new market report published by Transparency Market Research is Epigenetics Drugs and Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018
Published 10 September 2015
The global epigenetics drugs and diagnostics technologies market is thoroughly studied in a recent research report published by Transparency Market Research. The report, titled “Epigenetics Drugs and Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018”, states that the market had a net worth of US$1.6 billion in 2011. Growing at an extremely dynamic CAGR of 19.4% from 2012 and 2018, the global epigenetics drugs and diagnostics technologies market is projected to rise to US$5.7 billion by 2018.Epigenetics refers to a regulatory mechanism that controls gene expression without changing the genetic sequence of human DNAs. Epigenetic drugs make possible the reversal of the aberrant gene expression that can lead to a number of disease states.
The global epigenetics drugs and diagnostics technologies market is chiefly driven by factors such as rising population of geriatrics and the rising incidences of a variety of cancers across the globe. Epigenetic changes to cells are the early events in the development of cancers and are also reversible. Thus, the healthcare industry is increasingly giving importance to the research on various aspects of cancer epigenetics. The role of two major epigenetic changes including histone modifications and DNA methylation are being studied on a wide level across the globe. The market is also giving paying increased attention to the study of novel epigenetic markers for cancers. A number of drugs targeting epigenetic changes are being studied on a global level, which can prove effective individually or in combination with other conventional cancer medicines.
The market for epigenetic drugs and diagnostics technologies is studied by the report based on three chief categories: epigenetic drugs by mechanism of action, types of epigenetic diagnostic technologies, and chief regional market for epigenetic drugs and diagnostic technologies.The market segment of epigenetic drugs is further segmented into DNMT (DNA Methyltransferase) inhibitors and HDAC (Histone Deacetylase) inhibitors. Among these two key varieties of epigenetic inhibitors, DNMT inhibitors account for a larger market share due to their effectiveness in targeting cancerous cells.
The market segment of epigenetic diagnostic technologies is further segmented into DNA methylation and Chromatin Immunoprecipitation (ChIP) technology. Of these, the DNA methylation technique is mostly preferred as it has been tried and tested over the years.Among the key regional markets studied by the report, the market for epigenetic drugs and diagnostic techniques in North America currently accounts for nearly half of the overall market share. In the forecast period, the Asia Pacific market will provide significant growth opportunities for the market due to a high prevalence of a variety of cancers in these regions; Asia is host to nearly half of all the new cancer cases being observed globally. The epigenetic drugs market is highly consolidate as it features only four drugs: Eisai Pharmaceuticals’ Dacogen, Merck’s Zolinza, and Celgene’s Vidaza and Istodax. Of these, Celgene’s drugs accounted for a nearly 60% market share in 2011.
Browse the full Epigenetics Drugs and Diagnostic Technologies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018 report at http://www.transparencymarketresearch.com/epigenetics-market.html
The report presents detailed profiles of some of the key vendors operating in the global market for epigenetic drugs and diagnostic technologies, including Acetylon Pharmaceuticals, Inc., Eisai Pharmaceuticals, Celenge, Merck, Pharmacyclics, 4SC AG, Illumina Inc., Astex Pharmaceuticals Inc., Epigentek Group Inc., Celleron Therapeutics Ltd., Epizyme, Inc., Chroma Therapeutics Ltd., CellCentric Ltd., Promega Corporation, Oncolys BioPharma Inc., Spectrum Pharmaceuticals, EnVivo Pharmaceuticals Inc., Merck & Company Inc., Valirx Plc, and Novartis International.
About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.
TMR’s data repository is continuously updated and revised by a team of research experts so that it always reflects the latest trends and information. With extensive research and analysis capabilities, Transparency Market Research employs rigorous primary and secondary research techniques to develop distinctive data sets and research material for business reports.
Contact
Mr. Nachiket
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Share on Social Media
Contact Information
Mr. Rohit Bhisey
Transparency Market Research
State Tower, 90 State Street,
Suite 700,
Albany
12207
+91- 8600924083
http://www.transparencymarketresearch.com/
Other Industry News
Ready to start publishing
Sign Up today!
